Intervention Helps Clinicians Meet Guidelines for Prescribing Diabetes, Heart Drugs
Patients who have diabetes and heart disease do best when both conditions are treated according to established guidelines, but far too many are not prescribed the effective therapies. A recent study — designed and led by the Duke Clinical Research Institute (DCRI) and an academic steering committee — found that a coordinated care approach between cardiologists and diabetes specialists resulted in more patients receiving the recommended therapies. The study was funded by Boehringer Ingelheim and Eli Lilly and Company.
EMPA-KIDNEY Trial shows benefits for CKD in broad range of patients
A recent trial of empagliflozin expanded the understanding of how the drug can slow chronic kidney disease in a wide range of patients, lowering the risk of disease progression and death from cardi
Study Confirms No Benefit to Taking Ivermectin for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between parti
Trial finds common malaria prevention regimen reduces complications of sickle cell anemia in Kenyan children
A study by the Duke Clinical Research Institute comparing three treatment methods of preventing malaria in children with sickle cell anemia (SCA) found one method reduces common complications of the disease. EPiTOMISE: Enhancing Preventive Therapy Of Malaria in Children with Sickle cell anemia in East Africa, was conducted among children with SCA in Homa Bay, Kenya, where malaria is common. It evaluated the effects of a monthly combination of sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) or a monthly combination of dihydroartemisinin-piperaquine (DP) against the standard of care in Kenya, Proguanil.
Largest Randomized Trial Evaluates Steroids for Infant Heart Surgery
Less complex heart patients may benefit, but not without risk
Chest Pain Patients Benefit from Precision Diagnostic Testing Approach
A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.
Comparative Study of Two Heart Failure Drugs Finds No Difference in Outcomes
In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths,
Study Finds No Benefit to Taking Fluvoxamine for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the
Out of the Hospital, Not Out of the Woods
New research shows COVID-19 patients have a higher likelihood of heart failure post-discharge
A Win-Win: DCRI study shows pulmonary rehab in COPD patients reduces health care costs while improving patient health
Pulmonary rehabilitation is an important evidenced-based treatment to improve health and quality of life for people living with Chronic Obstructive Pulmonary Disease (COPD). Now, new research from the Duke Clinical Research Institute has shown that the benefits of pulmonary rehabilitation are likely to extend beyond the patient to reduce costs for the health care system as well – with an estimated savings of more than $5,000 per patient.